

# Nã°ria Plana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4422001/publications.pdf>

Version: 2024-02-01

56  
papers

1,451  
citations

304743

22  
h-index

361022

35  
g-index

61  
all docs

61  
docs citations

61  
times ranked

1952  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. American Journal of Cardiology, 2008, 102, 1187-1193.e1.	1.6	153
2	Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. Journal of Lipid Research, 2015, 56, 737-746.	4.2	133
3	Low HDL and high triglycerides predict COVID-19 severity. Scientific Reports, 2021, 11, 7217.	3.3	122
4	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 157-164.	3.0	64
5	Familial hypercholesterolemia in a European Mediterranean population – Prevalence and clinical data from 2.5 million primary care patients. Journal of Clinical Lipidology, 2017, 11, 1013-1022.	1.5	61
6	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. International Journal of Molecular Sciences, 2019, 20, 3151.	4.1	58
7	Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis, 2019, 284, 245-252.	0.8	55
8	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels – The zero-LDL hypothesis. Journal of Clinical Lipidology, 2018, 12, 292-299.e3.	1.5	51
9	Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific Reports, 2017, 7, 5596.	3.3	41
10	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. Journal of Clinical Medicine, 2019, 8, 1793.	2.4	40
11	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. Clínica E Investigación en Arteriosclerosis, 2016, 28, 71-78.	0.8	35
12	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. Journal of Clinical Medicine, 2019, 8, 1080.	2.4	33
13	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. Atherosclerosis, 2019, 287, 89-92.	0.8	29
14	APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis, 2015, 240, 98-104.	0.8	28
15	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovascular Diabetology, 2016, 15, 107.	6.8	28
16	Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. Journal of Clinical Lipidology, 2016, 10, 92-100.e1.	1.5	27
17	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. Current Cardiology Reports, 2020, 22, 66.	2.9	26
18	Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: – Herniated – HDL, a common feature in diabetes. Scientific Reports, 2016, 6, 19249.	3.3	25

#	ARTICLE	IF	CITATIONS
19	Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60. Revista Española De Cardiología, 2016, 69, 342-343.	1.2	24
20	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 2015, 238, 213-219.	0.8	23
21	Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real. Revista Española De Cardiología, 2018, 71, 1010-1017.	1.2	23
22	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. Atherosclerosis, 2017, 262, 107-112.	0.8	22
23	Registro Nacional de Dislipemias de la Sociedad Española de Arteriosclerosis: situación actual. Clínica E Investigación En Arteriosclerosis, 2017, 29, 248-253.	0.8	20
24	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. Journal of Nutritional Biochemistry, 2014, 25, 642-646.	4.2	19
25	Heterozygous Familial Hypercholesterolaemic Patients have Increased Arterial Stiffness, as Determined using the Augmentation Index. Journal of Atherosclerosis and Thrombosis, 2011, 18, 1110-1116.	2.0	18
26	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children: The DECOFIN project. Atherosclerosis, 2018, 278, 210-216.	0.8	18
27	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. American Journal of Cardiology, 2017, 119, 742-748.	1.6	17
28	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids in Health and Disease, 2019, 18, 216.	3.0	16
29	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. Journal of Clinical Lipidology, 2018, 12, 211-218.	1.5	14
30	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. Journal of Clinical Lipidology, 2018, 12, 1452-1462.	1.5	14
31	Actualización de las tablas de planificación terapéutica hipocolesterolemizante orientadas a la obtención de los objetivos terapéuticos. Clínica E Investigación En Arteriosclerosis, 2019, 31, 271-277.	0.8	13
32	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis, 2022, 349, 211-218.	0.8	12
33	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. Atherosclerosis, 2018, 270, 117-122.	0.8	11
34	Diferencias clínicas y genéticas de los pacientes con hipercolesterolemia familiar heterocigota con y sin diabetes mellitus tipo 2. Revista Española De Cardiología, 2020, 73, 718-724.	1.2	11
35	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. Revista Española De Cardiología (English Ed ), 2018, 71, 1010-1017.	0.6	10
36	Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders. Journal of Clinical Lipidology, 2016, 10, 330-338.e2.	1.5	9

#	ARTICLE	IF	CITATIONS
37	Valor de los parẮmetros lipẮdicos y apoproteicos para la detecciĂ³n de hipercolesterolemia familiar en la infancia. Proyecto DECOPIN. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2018, 30, 170-178.	0.8	9
38	Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. Atherosclerosis, 2020, 292, 42-51.	0.8	9
39	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1594-1603.	2.6	9
40	Serum glycoproteins A and B assessed by 1H-NMR in familial hypercholesterolemia. Atherosclerosis, 2021, 330, 1-7.	0.8	9
41	Hipercolesterolemia familiar en la infancia y la adolescencia: una realidad oculta. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2017, 29, 129-140.	0.8	8
42	Causas de no consecuciĂ³n del objetivo terapĂ©utico del colesterol de las lipoproteĂnas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de LĂpidos y Riesgo Vascular. Estudio EROMOT. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2018, 30, 1-9.	0.8	8
43	EstẮndares SEA 2019 para el control global del riesgo cardiovascular. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2019, 31, 1-43.	0.8	8
44	Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. Cardiovascular Drugs and Therapy, 1997, 11, 653-658.	2.6	7
45	Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia. Atherosclerosis, 2021, 320, 47-52.	0.8	7
46	Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 718-724.	0.6	6
47	Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection. Biomedicines, 2020, 8, 353.	3.2	6
48	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2014, 26, 58-65.	0.8	5
49	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk. Frontiers in Physiology, 2021, 12, 781789.	2.8	5
50	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. Frontiers in Endocrinology, 2021, 12, 775677.	3.5	4
51	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2020, 32, 49-58.	0.8	3
52	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. ClẮnica E InvestigaciĂ³n En Arteriosclerosis (English Edition), 2021, 33, 138-147.	0.2	2
53	PatrĂ³n de metilaciĂ³n en ADN de sujetos hipertrigliceridĂ©micos. ClẮnica E InvestigaciĂ³n En Arteriosclerosis, 2022, 34, 27-32.	0.8	2
54	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 519-520.	0.6	1

#	ARTICLE	IF	CITATIONS
55	El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes fenotipo de hipercolesterolemia familiar. Clínica E Investigación En Arteriosclerosis, 2021, 33, 138-147.	0.8	1
56	Letter to Editor: Increased Presence of Remnant Lipoprotein Cholesterol in The Hdl of Diabetic Subjects. Annals of Clinical and Laboratory Science, 2016, 46, 229-32.	0.2	0